Sitagliptin Shows Promise in Overcoming Gemcitabine Resistance in Pancreatic Cancer: SITGEM-CARE Phase II Trial
Gemcitabine-based chemotherapy remains an important treatment option for pancreatic ductal adenocarcinoma (PDAC), but the development of drug resistance significantly limits its clinical effectiveness. Elevated ribonucleotide reductase (RNR) activity, particularly involving its RRM1 and RRM2 subunits, is implicated in gemcitabine resistance by maintaining intracellular nucleotide pools and reducing the drug’s effectiveness. Researchers investigated sitagliptin, an established dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes, as a potential chemosensitizing agent.
Lupin Secures U.S. FDA Approval for Amifampridine Tablets, Eligible for 180-Day Shared Generic Exclusivity
Lupin Limited, a global pharmaceutical company headquartered in Mumbai, India, has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amifampridine Tablets, 10 mg. The approval represents an addition to the company’s generic pharmaceutical portfolio in the U.S. market and provides an opportunity to expand access to an established treatment option.
Zydus Secures USFDA Approval for Estradiol and Levonorgestrel Transdermal System with 180-Day CGT Exclusivity Eligibility
Zydus Lifesciences Limited announced on October 21, 2026, that the United States Food and Drug Administration (USFDA) had granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. The product is a generic equivalent of Climara Pro, a hormone therapy used in postmenopausal women. The approval expands Zydus’s portfolio of generic pharmaceutical products in the US market.
Prof GIUSEPPE MANCIA
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 1
Prof. Enrico Agabiti Rosei at ESH 2019 Milan part 2
Professor Dame Anna Dominiczak at ESH 2019 Milan
